Schering-Plough withdraws EU asthma inhaler application
This article was originally published in Scrip
Executive Summary
Schering-Plough (Merck) has withdrawn its centralised EU application for a fixed-dose pressurised asthma inhaler, Zenhale, which combined its corticosteroid mometasone furoate (Asmanex) plus the off-patent long-acting beta2-agonist formoterol fumarate (Novartis's Foradil).